lobbying_activities: 1986622

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1986622	7830c1a3-b481-425a-ba64-4874b49489e9	Q2	RED+BLUE STRATEGIES	400693064	COHERUS BIOSCIENCES	2017	second_quarter	PHA	S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications. S.934 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. H.R. 2797 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. Issues related to the treatment of biosimilar medications in Medicare Part B and D programs. Issues related to the maintenance of current IPR laws.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE	60000		0	0	2017-07-13T13:01:35.477000-04:00